EP3538551 - CD46-SPECIFIC EFFECTOR CELLS AND USES THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 08.10.2021 Database last updated on 19.10.2024 | |
Former | The application has been published Status updated on 23.09.2019 | ||
Former | The international publication has been made Status updated on 19.05.2018 | Most recent event Tooltip | 18.10.2024 | New entry: Date of cancellation oral proceedings | Applicant(s) | For all designated states Fortis Therapeutics, Inc. 11099 North Torrey Pines Road Suite 290 La Jolla, California 92037 / US | [2019/38] | Inventor(s) | 01 /
NASOFF, Marc 11099 North Torrey Pines Road Suite 290 La Jolla California 92037 / US | 02 /
PARK, Joshua 11099 North Torrey Pines Road Suite 290 La Jolla California 92037 / US | [2019/38] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [N/P] |
Former [2019/38] | HGF Limited 8th Floor 140 London Wall London EC2Y 5DN / GB | Application number, filing date | 17870332.8 | 10.11.2017 | [2019/38] | WO2017US61153 | Priority number, date | US201662420508P | 10.11.2016 Original published format: US 201662420508 P | [2019/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018089829 | Date: | 17.05.2018 | Language: | EN | [2018/20] | Type: | A1 Application with search report | No.: | EP3538551 | Date: | 18.09.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.05.2018 takes the place of the publication of the European patent application. | [2019/38] | Search report(s) | International search report - published on: | US | 17.05.2018 | (Supplementary) European search report - dispatched on: | EP | 14.10.2020 | Classification | IPC: | C07K14/725, C07K16/30, C07K16/28, C12N5/0783, C12N15/64, A61K39/00 | [2020/46] | CPC: |
C07K16/2896 (EP,US);
A61K2239/48 (EP,US);
A61K2239/58 (EP,US);
A61K38/177 (US);
A61K38/1774 (US);
A61K38/191 (US);
A61K38/20 (US);
A61K38/2013 (US);
A61K38/2046 (US);
A61K38/208 (US);
A61K38/2086 (US);
A61K38/217 (US);
A61K39/3955 (US);
A61K39/4611 (EP,US);
A61K39/4631 (EP,US);
A61K39/464412 (EP,US);
A61K39/464429 (EP,US);
A61P35/00 (EP,US);
C07K14/7051 (EP,US);
C07K14/70517 (US);
C07K14/70521 (US);
C07K14/70578 (US);
C07K19/00 (US);
C12N15/63 (US);
C12N5/0638 (EP,US);
C12N5/0646 (EP,US);
A61K2039/505 (EP);
A61K2039/54 (US);
A61K2039/545 (US);
A61K2039/572 (US);
A61K2039/884 (EP,US);
A61K31/675 (US);
A61K31/7076 (US);
A61K45/06 (US);
A61K9/0019 (US);
A61K9/0029 (US);
C07K2317/55 (US);
C07K2317/565 (US);
C07K2317/622 (EP,US);
C07K2317/73 (EP,US);
C07K2319/02 (US);
C07K2319/03 (EP,US);
|
Former IPC [2019/38] | C07K14/725, C07K16/30, C07K16/28, C12N5/0783, C12N15/64 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/38] | Title | German: | CD46-SPECIFISCHE EFFEKTORZELLEN UND VERWENDUNGEN DAVON | [2019/38] | English: | CD46-SPECIFIC EFFECTOR CELLS AND USES THEREOF | [2019/38] | French: | CELLULES EFFECTRICES SPÉCIFIQUES DE CD46 ET LEURS UTILISATIONS | [2019/38] | Entry into regional phase | 24.05.2019 | National basic fee paid | 24.05.2019 | Search fee paid | 24.05.2019 | Designation fee(s) paid | 24.05.2019 | Examination fee paid | Examination procedure | 11.05.2021 | Amendment by applicant (claims and/or description) | 07.10.2021 | Despatch of a communication from the examining division (Time limit: M06) | 25.03.2022 | Reply to a communication from the examining division | 16.10.2024 | Cancellation of oral proceeding that was planned for 22.10.2024 | 22.10.2024 | Date of oral proceedings (cancelled) | Fees paid | Renewal fee | 09.04.2020 | Renewal fee patent year 03 | 12.05.2021 | Renewal fee patent year 04 | 09.02.2022 | Renewal fee patent year 05 | 28.11.2022 | Renewal fee patent year 06 | 22.11.2023 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 30.11.2019 | 03   M06   Fee paid on   09.04.2020 | 30.11.2020 | 04   M06   Fee paid on   12.05.2021 | 30.11.2021 | 05   M06   Fee paid on   09.02.2022 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2016040683 (UNIV CALIFORNIA [US]); | [Y]WO2016100985 (DANA FARBER CANCER INST INC [US]); | International search | [Y]WO2016019300 (NOVARTIS AG [CH], et al); | [Y]WO2016040683 (UNIV CALIFORNIA [US]); | [Y]WO2016042461 (MOLMED SPA [IT]) |